114 related articles for article (PubMed ID: 18096386)
1. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.
Santella JB; Gardner DS; Yao W; Shi C; Reddy P; Tebben AJ; DeLucca GV; Wacker DA; Watson PS; Welch PK; Wadman EA; Davies P; Solomon KA; Graden DM; Yeleswaram S; Mandlekar S; Kariv I; Decicco CP; Ko SS; Carter PH; Duncia JV
Bioorg Med Chem Lett; 2008 Jan; 18(2):576-85. PubMed ID: 18096386
[TBL] [Abstract][Full Text] [Related]
2. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.
Gardner DS; Santella JB; Tebben AJ; Batt DG; Ko SS; Traeger SC; Welch PK; Wadman EA; Davies P; Carter PH; Duncia JV
Bioorg Med Chem Lett; 2008 Jan; 18(2):586-95. PubMed ID: 18160284
[TBL] [Abstract][Full Text] [Related]
3. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
De Lucca GV; Kim UT; Vargo BJ; Duncia JV; Santella JB; Gardner DS; Zheng C; Liauw A; Wang Z; Emmett G; Wacker DA; Welch PK; Covington M; Stowell NC; Wadman EA; Das AM; Davies P; Yeleswaram S; Graden DM; Solomon KA; Newton RC; Trainor GL; Decicco CP; Ko SS
J Med Chem; 2005 Mar; 48(6):2194-211. PubMed ID: 15771462
[TBL] [Abstract][Full Text] [Related]
4. Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.
Dhar TG; Yang G; Davies P; Malley MF; Gougoutas JZ; Wu DR; Barrish JC; Carter PH
Bioorg Med Chem Lett; 2009 Jan; 19(1):96-9. PubMed ID: 19010676
[TBL] [Abstract][Full Text] [Related]
5. Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.
De Lucca GV; Kim UT; Johnson C; Vargo BJ; Welch PK; Covington M; Davies P; Solomon KA; Newton RC; Trainor GL; Decicco CP; Ko SS
J Med Chem; 2002 Aug; 45(17):3794-804. PubMed ID: 12166951
[TBL] [Abstract][Full Text] [Related]
6. Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.
Varnes JG; Gardner DS; Santella JB; Duncia JV; Estrella M; Watson PS; Clark CM; Ko SS; Welch P; Covington M; Stowell N; Wadman E; Davies P; Solomon K; Newton RC; Trainor GL; Decicco CP; Wacker DA
Bioorg Med Chem Lett; 2004 Apr; 14(7):1645-9. PubMed ID: 15026042
[TBL] [Abstract][Full Text] [Related]
7. 2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.
Watson PS; Jiang B; Harrison K; Asakawa N; Welch PK; Covington M; Stowell NC; Wadman EA; Davies P; Solomon KA; Newton RC; Trainor GL; Friedman SM; Decicco CP; Ko SS
Bioorg Med Chem Lett; 2006 Nov; 16(21):5695-9. PubMed ID: 16931001
[TBL] [Abstract][Full Text] [Related]
8. CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.
Pruitt JR; Batt DG; Wacker DA; Bostrom LL; Booker SK; McLaughlin E; Houghton GC; Varnes JG; Christ DD; Covington M; Das AM; Davies P; Graden D; Kariv I; Orlovsky Y; Stowell NC; Vaddi KG; Wadman EA; Welch PK; Yeleswaram S; Solomon KA; Newton RC; Decicco CP; Carter PH; Ko SS
Bioorg Med Chem Lett; 2007 Jun; 17(11):2992-7. PubMed ID: 17418570
[TBL] [Abstract][Full Text] [Related]
9. Small molecule antagonists for chemokine CCR3 receptors.
Willems LI; Ijzerman AP
Med Res Rev; 2010 Sep; 30(5):778-817. PubMed ID: 19967721
[TBL] [Abstract][Full Text] [Related]
10. Strategy for the enantioselective synthesis of trans-2,4-disubstituted piperidines: application to the CCR3 antagonist IS811.
Kauffman GS; Watson PS; Nugent WA
J Org Chem; 2006 Nov; 71(23):8975-7. PubMed ID: 17081035
[TBL] [Abstract][Full Text] [Related]
11. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Batt DG; Houghton GC; Roderick J; Santella JB; Wacker DA; Welch PK; Orlovsky YI; Wadman EA; Trzaskos JM; Davies P; Decicco CP; Carter PH
Bioorg Med Chem Lett; 2005 Feb; 15(3):787-91. PubMed ID: 15664858
[TBL] [Abstract][Full Text] [Related]
12. Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.
Watson RJ; Allen DR; Birch HL; Chapman GA; Galvin FC; Jopling LA; Knight RL; Meier D; Oliver K; Meissner JW; Owen DA; Thomas EJ; Tremayne N; Williams SC
Bioorg Med Chem Lett; 2008 Jan; 18(1):147-51. PubMed ID: 18032038
[TBL] [Abstract][Full Text] [Related]
13. Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.
Nitta A; Iura Y; Tomioka H; Sato I; Morihira K; Kubota H; Morokata T; Takeuchi M; Ohta M; Tsukamoto S; Imaoka T; Takahashi T
Bioorg Med Chem Lett; 2012 Aug; 22(15):4951-4. PubMed ID: 22749826
[TBL] [Abstract][Full Text] [Related]
14. The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists.
Ting PC; Lee JF; Wu J; Umland SP; Aslanian R; Cao J; Dong Y; Garlisi CG; Gilbert EJ; Huang Y; Jakway J; Kelly J; Liu Z; McCombie S; Shah H; Tian F; Wan Y; Shih NY
Bioorg Med Chem Lett; 2005 Mar; 15(5):1375-8. PubMed ID: 15713390
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.
Furber M; Alcaraz L; Luckhurst C; Bahl A; Beaton H; Bowers K; Collington J; Denton R; Donald D; Kinchin E; MacDonald C; Rigby A; Riley R; Soars M; Springthorpe B; Webborn P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7702-6. PubMed ID: 23142617
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional analyses before and after suppression of immediate hypersensitivity reactions by CCR3 blockade in eyes with experimental allergic conjunctivitis.
Komatsu N; Miyazaki D; Tominaga T; Kuo CH; Namba S; Takeda S; Higashi H; Inoue Y
Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5307-13. PubMed ID: 18658092
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.
Sato I; Morihira K; Inami H; Kubota H; Morokata T; Suzuki K; Iura Y; Nitta A; Imaoka T; Takahashi T; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2008 Sep; 16(18):8607-18. PubMed ID: 18752960
[TBL] [Abstract][Full Text] [Related]
18. Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.
Furber M; Alcaraz L; Luckhurst C; Bahl A; Beaton H; Bowers K; Collington J; Denton R; Donald D; Kinchin E; MacDonald C; Rigby A; Riley R; Soars M; Springthorpe B; Webborn P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7707-10. PubMed ID: 23116889
[TBL] [Abstract][Full Text] [Related]
19. Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
Bahl A; Barton P; Bowers K; Caffrey MV; Denton R; Gilmour P; Hawley S; Linannen T; Luckhurst CA; Mochel T; Perry MW; Riley RJ; Roe E; Springthorpe B; Stein L; Webborn P
Bioorg Med Chem Lett; 2012 Nov; 22(21):6694-9. PubMed ID: 23021991
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.
Sato I; Morihira K; Inami H; Kubota H; Morokata T; Suzuki K; Ohno K; Iura Y; Nitta A; Imaoka T; Takahashi T; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2009 Aug; 17(16):5989-6002. PubMed ID: 19620010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
